Humacyte, Inc. (HUMA)
0.4672
-0.01
(-2.26%)
USD |
NASDAQ |
Oct 07, 10:00
Humacyte Max Drawdown (5Y) : 96.76% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 96.76% |
| August 31, 2026 | 96.76% |
| July 31, 2026 | 96.62% |
| June 30, 2026 | 96.62% |
| May 31, 2026 | 96.62% |
| April 30, 2026 | 96.62% |
| March 31, 2026 | 96.62% |
| February 28, 2026 | 94.78% |
| January 31, 2026 | 94.35% |
| December 31, 2025 | 94.35% |
| November 30, 2025 | 93.41% |
| October 31, 2025 | 93.23% |
| September 30, 2025 | 93.23% |
| August 31, 2025 | 93.23% |
| July 31, 2025 | 93.23% |
| June 30, 2025 | 93.23% |
| May 31, 2025 | 93.23% |
| April 30, 2025 | 93.23% |
| March 31, 2025 | 89.96% |
| February 28, 2025 | 88.29% |
| January 31, 2025 | 88.29% |
| December 31, 2024 | 88.29% |
| November 30, 2024 | 88.29% |
| October 31, 2024 | 88.29% |
| September 30, 2024 | 88.29% |
| Date | Value |
|---|---|
| August 31, 2024 | 88.29% |
| July 31, 2024 | 88.29% |
| June 30, 2024 | 88.29% |
| May 31, 2024 | 88.29% |
| April 30, 2024 | 88.29% |
| March 31, 2024 | 88.29% |
| February 29, 2024 | 88.29% |
| January 31, 2024 | 88.29% |
| December 31, 2023 | 88.29% |
| November 30, 2023 | 88.29% |
| October 31, 2023 | 88.17% |
| September 30, 2023 | 88.11% |
| August 31, 2023 | 88.11% |
| July 31, 2023 | 88.11% |
| June 30, 2023 | 88.11% |
| May 31, 2023 | 88.11% |
| April 30, 2023 | 88.11% |
| March 31, 2023 | 88.11% |
| February 28, 2023 | 88.11% |
| January 31, 2023 | 88.11% |
| December 31, 2022 | 88.11% |
| November 30, 2022 | 83.11% |
| October 31, 2022 | 81.52% |
| September 30, 2022 | 81.11% |
| August 31, 2022 | 81.11% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Amgen, Inc. | 24.86% |
| Altimmune, Inc. | 93.57% |
| Protalix Biotherapeutics, Inc. | 94.38% |
| Taysha Gene Therapies, Inc. | 98.14% |
| Agenus, Inc. | 98.84% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -74.50 |
| Beta (5Y) | 2.439 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 101.0% |
| Historical Sharpe Ratio (5Y) | -0.4962 |
| Historical Sortino (5Y) | -1.101 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 39.53% |